Cargando…

A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy

Cavernous nerve injury is an important cause of erectile dysfunction (ED). Although protective nerve technology has been widely used in nerve-sparing radical prostatectomy (nsRP), the incidence of ED is still very high after surgery. The purpose of our study was to evaluate erectile function (EF) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ming, Che, Ji-Zhong, Liu, Yi-Dong, Wang, Hong-Xiang, Huang, Yan-Ping, Lv, Xiang-Guo, Liu, Wei, Lu, Mu-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491044/
https://www.ncbi.nlm.nih.gov/pubmed/34975069
http://dx.doi.org/10.4103/aja202189
_version_ 1784793211031519232
author Zhang, Ming
Che, Ji-Zhong
Liu, Yi-Dong
Wang, Hong-Xiang
Huang, Yan-Ping
Lv, Xiang-Guo
Liu, Wei
Lu, Mu-Jun
author_facet Zhang, Ming
Che, Ji-Zhong
Liu, Yi-Dong
Wang, Hong-Xiang
Huang, Yan-Ping
Lv, Xiang-Guo
Liu, Wei
Lu, Mu-Jun
author_sort Zhang, Ming
collection PubMed
description Cavernous nerve injury is an important cause of erectile dysfunction (ED). Although protective nerve technology has been widely used in nerve-sparing radical prostatectomy (nsRP), the incidence of ED is still very high after surgery. The purpose of our study was to evaluate erectile function (EF) and penile length in the non-erectile state (PLNES) following scheduled phosphodiesterase 5 inhibitor (PDE5i), vacuum erectile device (VED) treatment, and combination therapy after nsRP. One hundred patients with localized prostate cancer and normal EF were randomized to scheduled PDE5i group, VED treatment group, a combined treatment group, and the control group without any intervention. The International Index of Erectile Function-5 (IIEF-5) scores and PLNES were evaluated after 6 months and 12 months of treatment. Sexual Encounter Profile (SEP-Question 2 and SEP-Question 3) were evaluated after 12 months of treatment. Ninety-one of the 100 randomized patients completed the study. We found that the 5 mg tadalafil once a day (OaD) combined with VED can help improve IIEF-5 scores in nsRP patients after both 6 months and 12 months. VED alone or combined with tadalafil OaD can help patients maintain PLNES. VED combined with tadalafil OaD can improve the rate of successful penetration (SEP-Question 2) after 12 months. There were no significant differences in the return to target EF after 12 months among the groups. No significant correlation was noted between the variables and return to target EF (IIEF ≥ 17), and between the variables and effective shortening of the patient's penis (shortening ≥ 1 cm) after 12 months of intervention.
format Online
Article
Text
id pubmed-9491044
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-94910442022-09-22 A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy Zhang, Ming Che, Ji-Zhong Liu, Yi-Dong Wang, Hong-Xiang Huang, Yan-Ping Lv, Xiang-Guo Liu, Wei Lu, Mu-Jun Asian J Androl Original Article Cavernous nerve injury is an important cause of erectile dysfunction (ED). Although protective nerve technology has been widely used in nerve-sparing radical prostatectomy (nsRP), the incidence of ED is still very high after surgery. The purpose of our study was to evaluate erectile function (EF) and penile length in the non-erectile state (PLNES) following scheduled phosphodiesterase 5 inhibitor (PDE5i), vacuum erectile device (VED) treatment, and combination therapy after nsRP. One hundred patients with localized prostate cancer and normal EF were randomized to scheduled PDE5i group, VED treatment group, a combined treatment group, and the control group without any intervention. The International Index of Erectile Function-5 (IIEF-5) scores and PLNES were evaluated after 6 months and 12 months of treatment. Sexual Encounter Profile (SEP-Question 2 and SEP-Question 3) were evaluated after 12 months of treatment. Ninety-one of the 100 randomized patients completed the study. We found that the 5 mg tadalafil once a day (OaD) combined with VED can help improve IIEF-5 scores in nsRP patients after both 6 months and 12 months. VED alone or combined with tadalafil OaD can help patients maintain PLNES. VED combined with tadalafil OaD can improve the rate of successful penetration (SEP-Question 2) after 12 months. There were no significant differences in the return to target EF after 12 months among the groups. No significant correlation was noted between the variables and return to target EF (IIEF ≥ 17), and between the variables and effective shortening of the patient's penis (shortening ≥ 1 cm) after 12 months of intervention. Wolters Kluwer - Medknow 2021-12-28 /pmc/articles/PMC9491044/ /pubmed/34975069 http://dx.doi.org/10.4103/aja202189 Text en Copyright: ©The Author(s)(2022) https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Zhang, Ming
Che, Ji-Zhong
Liu, Yi-Dong
Wang, Hong-Xiang
Huang, Yan-Ping
Lv, Xiang-Guo
Liu, Wei
Lu, Mu-Jun
A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy
title A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy
title_full A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy
title_fullStr A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy
title_full_unstemmed A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy
title_short A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy
title_sort prospective randomized controlled study on scheduled pde5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491044/
https://www.ncbi.nlm.nih.gov/pubmed/34975069
http://dx.doi.org/10.4103/aja202189
work_keys_str_mv AT zhangming aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT chejizhong aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT liuyidong aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT wanghongxiang aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT huangyanping aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT lvxiangguo aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT liuwei aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT lumujun aprospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT zhangming prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT chejizhong prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT liuyidong prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT wanghongxiang prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT huangyanping prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT lvxiangguo prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT liuwei prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy
AT lumujun prospectiverandomizedcontrolledstudyonscheduledpde5iandvacuumerectiledevicesinthetreatmentoferectiledysfunctionafternervesparingprostatectomy